Literature DB >> 11587147

The treatment of dry eye.

M Calonge1.   

Abstract

The most widely used therapy for dry eye disease is tear replacement by topical artificial tears. Punctal occlusion to prevent the drainage of natural or artificial tears is the most common non-pharmacological treatment. These and other traditional therapies for dry eye disease are only palliative, however, as they replace or conserve the tears without necessarily correcting the underlying disease process. As our understanding of the pathology of dry eye disease improves, new treatment strategies are being developed. Topical anti-inflammatory and immunomodulatory agents, such as cyclosporin A, are under investigation in the treatment of dry eye, as it is anticipated that they will correct the vicious cycle of inflammation and cell damage on the ocular surface and lacrimal glands.

Entities:  

Mesh:

Year:  2001        PMID: 11587147     DOI: 10.1016/s0039-6257(00)00205-8

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  24 in total

1.  Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model.

Authors:  Hiroshi Toshida; Doan H Nguyen; Roger W Beuerman; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-14       Impact factor: 4.799

Review 2.  T helper cytokines in dry eye disease.

Authors:  Stephen C Pflugfelder; Rosa M Corrales; Cintia S de Paiva
Journal:  Exp Eye Res       Date:  2013-09-04       Impact factor: 3.467

Review 3.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 4.  Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues.

Authors:  Benjamin G Cooper; Ara Nazarian; Brian D Snyder; Mark W Grinstaff
Journal:  Biomaterials       Date:  2018-07-26       Impact factor: 12.479

5.  Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.

Authors:  Marco Coassin; Alessandro Lambiase; Nicola Costa; Alessandra De Gregorio; Roberto Sgrulletta; Marta Sacchetti; Luigi Aloe; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-01-14       Impact factor: 3.117

6.  No consequences of dietary n-3 polyunsaturated fatty acid deficiency on the severity of scopolamine-induced dry eye.

Authors:  Sabrina Viau; Bruno Pasquis; Marie-Annick Maire; Cynthia Fourgeux; Stéphane Grégoire; Niyazi Acar; Lionel Bretillon; Catherine P Creuzot-Garcher; Corinne Joffre
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-12-16       Impact factor: 3.117

7.  Longitudinal evidence on punctal plug use in an elderly population.

Authors:  Sulene L Chi; Kofi F Acquah; Michael J Richard; Paul P Lee; Frank A Sloan
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2012 Jul-Aug       Impact factor: 1.746

8.  Electronic enhancement of tear secretion.

Authors:  Mark Brinton; Jae Lim Chung; Andrea Kossler; Koung Hoon Kook; Jim Loudin; Manfred Franke; Daniel Palanker
Journal:  J Neural Eng       Date:  2015-12-10       Impact factor: 5.379

9.  Evaluation of Accessory Lacrimal Gland in Muller's Muscle Conjunctival Resection Specimens for Precursor Cell Markers and Biological Markers of Dry Eye Disease.

Authors:  Marwan Ali; Dhara Shah; Zeeshan Pasha; Sarmad H Jassim; Assraa Jassim Jaboori; Pete Setabutr; Vinay K Aakalu
Journal:  Curr Eye Res       Date:  2016-09-09       Impact factor: 2.424

10.  Amniotic membrane as a carrier for lacrimal gland acinar cells.

Authors:  S Schrader; Th Wedel; C Kremling; H Laqua; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.